≤30 years, thereby excluding the significant proportion of the T1D population diagnosed after 30 years of age. 12 None of these risk scores are used on a regular basis in clinical practice.
The overall objective of this study was to develop and validate a model for predicting CVD in a large cohort of T1D patients without a previous CVD event.
Methods

Study Design and Participants
The prediction model was developed by using 4996 adult patients with T1D attending the outpatient clinic at Steno Diabetes Center in Gentofte, Denmark, from January 1, 2001 , to September 30, 2013 . We excluded 682 (13.7%) patients with previous CVD and 8 (<1%) with no follow-up time, leaving 4306 patients for analysis.
The T1D population of the Steno Diabetes Center constitutes a representative subsample of the total Danish adult T1D population. 13 
Procedures
T1D was clinically diagnosed on the basis of phenotype according to the requirements in the Danish National Diabetes Quality Database: <30 years of age and treatment with insulin at diagnosis. Patients >30 years of age at diagnosis or who were initially using oral hypoglycemic drugs before treatment with insulin were classified as T1D patients if there was an absolute need for insulin to control blood glucose in combination with low C-peptide values or glutamic acid decarboxylase 65 antibody positivity.
Baseline was the first clinical examination occurring at least 1 year after diabetes diagnosis to ensure exclusion of extreme values of metabolic risk factors such as hemoglobin A 1c and lipids often present at the time of diagnosis.
Measurements and Definitions
Clinical characteristics were drawn from the electronic patient record at Steno Diabetes Center during the period 2001 to 2013. Data included age, height, weight, body mass index, sex, diabetes duration, insulin dose, use of lipid-lowering medication or antihypertensive treatment, smoking status, alcohol intake (units per week) and physical activity, hemoglobin A 1c , albuminuria, estimated glomerular filtration rate (eGFR), systolic and diastolic blood pressure, total cholesterol, high-density lipoprotein and low-density lipoprotein cholesterol, triglycerides, hemoglobin, potassium, sodium, and thyroid-stimulating hormone (TSH).
Brachial systolic and diastolic blood pressure were measured twice with an automated oscillometric blood pressure recorder according to guidelines for validated devices from the British Hypertension Society. 14 The average of the measurements was used. For patients with possible white-coat hypertension, home blood pressure monitoring was offered according to guidelines. 15 Hemoglobin A 1c was determined by standard high-performance liquid chromatography (normal range, 4.1%-6.4% [21-46 mmol/ mol]; Variant; Bio-Rad Laboratories, Munich, Germany), and serum creatinine concentration was determined by an enzymatic method (Hitachi 912; Roche Diagnostics, Mannheim, Germany).
Urinary albumin excretion ratio was measured in 24-hour sterile urine collections by enzyme immunoassay or from the urinary albumin creatinine ratio measured on a single random urine sample.
For patients with no measurements of glomerular filtration rate, we estimated the glomerular filtration rate (eGFR) from the Chronic Kidney Disease Epidemiology Collaboration standard equation 16 as recommended in the 2013 guidelines from the Kidney Disease Improving Global Outcomes foundation.
Total cholesterol, high-density lipoprotein cholesterol, triglycerides, plasma creatinine, urine creatinine, and urine albumin were measured by using the Hitachi 912 system (Roche Diagnostics, Mannheim, Germany). During 2010, the study laboratory gradually implemented the Vitros 5600 Integrated System (Ortho Clinical Diagnostics, Illkirch Cedex, France). All Vitros values were converted to correspond to Hitachi values. low-density lipoprotein cholesterol was calculated by using the Friedewald equation. 17 Other clinical measurements (potassium, sodium, and TSH) were obtained using standard methods.
C-peptide and glutamic acid decarboxylase antibodies were only available in a subset of patients (66% and 30%, respectively) and therefore not considered in the analyses.
Dichotomizing of the continuous variables was avoided when possible. 18 However, because data on physical activity, smoking, and alcohol intake were not recorded in a standardized manner over time, we categorized smoking status in to current smoker (Yes/No) and physical activity into regular physical active (Yes/No) using a cut point of ≥30 minutes per day. Alcohol intake was categorized in 3 classes (0, 1-20, and > 20 U/wk).
Also, because urine albumin was measured from a 24-hour urine collection in some patients and by spot urine samples in others, we classified patients into having normoalbuminuria, microalbuminuria, or macroalbuminuria rather than using the albumin measurement directly. 19 Furthermore, having macroalbuminuria is an indication for initiating further investigation and possibly treatment for nephropathy and may therefore have additional predictive information.
All Danish residents have a unique personal identification number recorded in the Danish Civil Registration System. 20 The clinical data were linked to mortality data from the Cause of Death Register 21 and to morbidity data from the Danish National Patient Register 22 using this personal identification number. Data on ethnicity were obtained from the Central Person Register. 23 The registers in Denmark are nationwide and cover all residents.
We defined CVD as a composite outcome of fatal and nonfatal events of ischemic heart disease, ischemic stroke, heart failure, and peripheral artery disease. Arrhythmia diagnosed before or at baseline was tested as a possible predictor for CVD. See Table I in the onlineonly Data Supplement for the specific International Classification of Diseases codes used.
According to Danish law, ethics approval and patient consent is not required for registry-based studies. Access and use of the described data are approved by the Danish Data Protection Agency (j-No: 2007-58-0015 and 2012-58-0009).
Statistical Analysis
Statistical analyses were performed in R version 3.1.3 (The R Foundation for Statistical Computing, www. R-project.org) and SAS version 9.2 (SAS Institute, Cary, NC).
All patients were followed until first CVD occurrence or death or until censor date September 30, 2013 (date of register extraction; 29 114 person-years). Median follow-up was 6.8 years (interquartile range, 2.9-10.9), during which 793 (18.4%) patients developed CVD.
For most determinants ≤5% of the values were missing. Eight percent of the patients had no blood pressure measurements at baseline. To avoid exclusion of patients with missing values which may infer biased results, 24 missing data on determinants were imputed by using the Multivariate Imputations by Chained Equations method 25 (mice package in R software) with missing-at-random assumptions. Twenty-five copies of the data, each with missing values suitably imputed, were independently assessed in the analyses described below. Estimates of parameters of interest were averaged across the copies according to Rubin rules. 26 The risk prediction model was developed by using a 2-stage approach. First a nonparametric, data-driven approach was used to identify potentially informative risk factors and interactions based on random forest and survival tree analysis. Second, Poisson regression analysis was used to derive the final prediction model based on the identified risk factors and interactions identified in the first step.
Details of the modeling process are as follows. In step 1, a random survival forest analysis was applied to rank the risk factors according to their permutation importance, and predictors with a negative importance score were excluded from further analysis (randomForestSRC package in R). Then, a survival tree model was fitted using the risk factors with a positive importance score (party package in by guest on April 18, 2017 http://circ.ahajournals.org/ Downloaded from R). 27 A survival tree is constructed using recursive partitioning. At each node of the survival tree, the recursive partitioning algorithm identifies the risk factor and the split in this factor which gives the maximal difference in CVD rates between the 2 resulting subgroups. This procedure is applied recursively until the tree has been grown to an optimal number of terminal leaves. The survival tree approach is a flexible method that can take into account high-level interactions between predictors.
In step 2, a Poisson regression analysis approach to model yearly incidence rates of CVD in T1D was applied, using log-person-time as the offset variable (stats package in R). Because it is well known that the risk of CVD of a person is not constant over time, 2, 3 the follow-up period of each participant was split into 1-year age bands (Epi package in R). 28 Hence, 1 patient may contribute with several records, 1 per follow-up interval. The informative risk factors and interactions identified in step 1 were tested. Also, because treated and untreated levels of blood pressure and lipids may have different meaning, we further included interactions with medication (antihypertensive treatment or lipid-lowering treatment) in the model. The ratio total:high-density lipoprotein cholesterol was also considered. Backward elimination was used to identify significant predictors of CVD, using a level of significance of 5%. In addition, we used clinical judgment, as is recommended, to choose between highly correlated predictors of equal predictive power. 29 Before analysis, predictors with a highly skewed distribution (triglycerides, eGFR and TSH) were log-transformed to improve model calibration.
The accuracy of the predicted CVD risk from the model was evaluated graphically by comparing means of estimated risk with the observed 5-and 10-year cumulative CVD incidence in deciles of estimated risk. The calibration of the prediction model was determined using Hosmer-Lemeshow test of goodness of fit (PredictABEL package in R). 30 The discriminative ability of the models was evaluated by using the C-statistic, which is an overall measure of the probability that the predicted CVD risk from the model is higher in a patient developing CVD than in a patient not developing CVD. 31 Confidence intervals were computed with 2000 stratified bootstrap replicates (pROC package in R). 32 Risk prediction models developed in 1 population are known to over-or underestimate the risk in other populations. 33 In the variable selection step, predictors are selected if they are estimated to be highly associated with the CVD outcome in the derivation data, irrespective of their true association with the outcome. This means that a predictor with an overestimated regression coefficient is more likely to be included than a predictor with an underestimated regression coefficient. 34 Hence, for the selected predictors, we would expect the estimated regression coefficients on average to be smaller in a different data set. To correct for the overestimation of the regression coefficients attributable to the variable selection, we applied postestimation parameter-wise shrinkage of the regression coefficients (shrink package in R), based on calibrating the linear predictor using leave-one-out cross-validation (Jacknife). 35 Using this approach, weak predictors less correlated with the CVD outcome are shrunken relatively more than the strong predictors in the model.
The shrunken risk prediction model was externally validated in the T1D population of the Funen Diabetes Database in Denmark. 36 As a sensitivity analysis, the model without shrinkage was tested as well. The validation population consisted of 2118 adult clinically diagnosed T1D patients from the same criteria as in the derivation cohort and without a previous CVD (13 635 person-years). Baseline was from 2003 and end of follow-up was the end of 2014. Median follow-up was 6.6 years (interquartile range, 4.0-9.1) during which 243 (11.5%) developed CVD (see Table 1 for further characteristics of the validation population). Because relatively few (<19%) in the Funen T1D patient population had ≥10 years of follow-up, validation was only performed for 5-year CVD risk prediction.
The performance of the Swedish T1D risk score, 11 the UKPDS risk engine 8 for type 2 diabetes mellitus and the atherosclerotic cardiovascular disease (ASCVD) risk equation 37, 38 for the general population was further assessed and compared with that of the shrunken risk prediction model (pROC package in R), in both the derivation and validation cohorts.
In a secondary analysis, we repeated the analysis for nonfatal and fatal ischemic heart disease and stroke as outcome.
Results
The patient population in the derivation data (Steno Diabetes Center) spanned almost the entire adult age range at baseline (18-90 years) with women constituting 46% of the population. Almost 1 in 3 patients was diagnosed with T1D after 30 years of age. The overall annual rate of CVD was 2.7%. After 5 and 10 years, 451 (10.5%) and 731 (17.0%) had developed CVD. Ischemic heart disease totaled 43% of CVD events; ischemic stroke was 20%, heart failure was 24%, and peripheral artery disease was 13% of the CVD events. A total of 182 (4.2%) patients died of causes other than CVD during follow-up.
T1D patients developing CVD during follow-up were older at study entry with a longer duration of diabetes mellitus and a higher proportion in antihypertensive and lipid-lowering treatment. Compared to patients without CVD, the lifestyle of this group of patients was relatively worse with a higher proportion of smokers and a larger intake of alcohol combined with a smaller proportion being physically active on a regular basis. The renal state of T1D patients developing CVD was worse with a higher proportion of micro-and macroalbuminuria and lower eGFR compared to those without CVD. There was no difference in the distribution of sex (Table II in From the random survival forest analyses in step 1 of the CVD risk model development, we excluded body mass index, migrant status, and insulin dose from further analysis (see Figure I in the online-only Data Supplement for variable importance). The survival tree analysis indicated a modifying effect of age on a number of risk factors in the prediction of CVD, including eGFR, diabetes duration, albuminuria, and lipids (see Figure II in the online-only Data Supplement). The final Poisson regression model included 10 risk factors: age, sex, diabetes duration, systolic blood pressure, low-density lipoprotein cholesterol, hemoglobin A 1c , albuminuria, glomerular filtration rate, smoking, and exercise. An interaction between eGFR and age was found. The rate ratios for the significant predictors with and without shrinkage are listed in Table 2 . Model parameters were relatively stable toward postestimation parameter-wise shrinkage (<5% shrinkage). The model equation and estimated model parameters are supplied in Table III in the online-only Data Supplement.
Internal validation in the derivation data gave a C-statistic of 0.826 (0.807-0.845) for a 5-year CVD event and 0.818 (0.802-0.833) for a 10-year CVD event, which is considered excellent discrimination. 39 The Hosmer-Lemeshow test showed good calibration (5-year CVD event: χ The C-statistic of the Swedish T1D risk score, the UKPDS risk engine, and the ASCVD risk equation were significantly lower than that of the developed CVD risk model in the derivation cohort (P≤0.031), and all showed poor calibration (P<0.001, Table 3 ). This is likely because of the difference in end points.
External validation in the Funen T1D patient population showed excellent discrimination with a C-statistic of 0.803 (0.767-0.839) for a 5-year CVD event, and the HosmerLemeshow test results showed good calibration (χ 2 =10.9, P=0.207). The overall annual rate of CVD was 1.8%. The calibration plot is shown in Figure 1A . The postestimation shrinkage of the parameters did not change the C-statistic of the model in the validation data but increased calibration slightly ( Figure IV in the online-only Data Supplement).
In the Funen validation cohort, the C-statistic for the Swedish T1D risk score was not statistically significantly lower than in the developed CVD model (P=0.377). However, both the Swedish T1D risk score, the UKPDS risk engine, and the ASCVD risk equation showed poor calibration (P<0.001; Table 3 ). Again, this is likely because of the difference in end points.
In the secondary analysis for nonfatal and fatal ischemic heart disease and stroke as outcome, we found the same risk factors to be significant in the Poisson regression model (see Table IV in the online-only Data Supplement). The performance of the model was slightly lower than for the composite CVD outcome (Table 3) . C-statistics and calibration plots for the Swedish T1D risk score, the UKPDS risk engine, and the ASCVD risk equation in the Funen validation cohort are shown in Figure 2 .
Discussion
Recently, the increasing role of prognosis research and the necessary methodological improvements were highlighted in a series of articles from leading experts in the field. [40] [41] [42] [43] Complying with these guidelines, we have derived a model for prediction of first CVD event in patients with T1D with excellent performance in both the derivation and validation data. The performance is comparable to that of the Swedish CVD risk equation 11 and higher than the performance of currently available risk prediction models for CVD in type 2 diabetes mellitus, including the UKPDS risk engine. 8, [44] [45] [46] The ability of the Swedish T1D risk score, 11 the UKPDS risk engine, 8 and the ASCVD risk equation 38 for predicting the composite CVD outcome in the Funen validation cohort were lower than that of the developed CVD risk model. This is partly because the existing risk scores were developed for a different outcome (ischemic heart disease alone or ischemic heart disease or stroke). However, the same result was found in relation to the prediction of ischemic heart disease or stroke, although this could be attributed, at least in part, to the difference in patient characteristics between the Funen validation cohort and the background populations for the existing risk scores.
There are few controlled studies of the effect of aspirin, lipid, and blood pressure-lowering therapy in T1D patients, but meta-analyses of these studies have shown a similar effect of treatment in T1D as in patients with type 2 diabetes mellitus. 47 It is crucial for the decision to implement these treatments in T1D patients that the risk of CVD can be correctly estimated. The need for T1D-specific CVD risk estimation has recently been highlighted by the American Heart For all patients, we had reliable information on previous and incident fatal and nonfatal CVD events from validated national registers of morbidity and mortality. We used a composite CVD end point including ischemic heart disease, ischemic stroke, heart failure, and peripheral artery disease. These are the 4 most serious CVD events associated with premature death and reduced quality of life among patients with T1D. 48 Although the underlying pathophysiology for these 4 events may be different, they share the same risk factors, and the strategies for primary prevention are similar, eg, promoting a healthy lifestyle and treating hypertension and dyslipidemia. 49, 50 There is no consensus on the optimal method for selecting variables for a prediction model, and different approaches have been used in the literature. 18 Although, univariable analysis of the candidate predictors is a commonly used first step, we did not perform such an initial screening of the predictors because this method may wrongly exclude potentially important variables if the association with CVD events is confounded by some of the other predictor variables. 29, 51 Instead, we used a data-driven approach as a first step to remove uninformative predictors. In the Poisson regression analysis, we used a backward elimination approach starting with a model including all the potentially informative predictor variables from the first step. Backward elimination is considered superior to the alternative forward selection approach. 18 In addition, we used clinical judgment in the variable selection, which is also recommended. 29 We applied multiple imputation of missing data to avoid having to exclude patients from the analysis. Studies have shown that a complete case analysis approach not only loses power but may lead to biased estimates of both the model outcomes and its predictors. 24 Multiple imputation is considered the optimal method for imputing missing data. 24 We corrected for the overestimation of the regression coefficients through postestimation parameter-wise shrinkage of the regression coefficients, and the shrunken model showed good calibration in the validation data.
The CVD risk model developed in this study was based on an unselected large cohort of T1D patients with detailed clinical data collected on a regular basis. The patient population spanned the entire adult age range and included both newly diagnosed patients and patients with long-standing T1D. The diagnosis of T1D was precise and clinically verified, which facilitated the inclusion of patients diagnosed after 30 years of age. Almost 1 in 3 patients in our T1D population was diagnosed after 30 years of age, which is in accordance with the distribution found in other studies 12, 52 ; information on this group of patients is particularly scarce in the literature.
The T1D population used for deriving the risk model was predominantly of Danish ancestry (>90%) which could explain why there was no statistically significant effect of including information of non-Danish ancestry in the model. However, it may also be that the comprehensive list of risk factors, otherwise included in the model, sufficiently explain ethnic differences in CVD risk among T1D patients. Nevertheless, because the cohort used for validating the present CVD risk model was also predominantly of Danish ancestry, further external validation in patient cohorts with a different ethnic mix is needed before widespread clinical implementation of the CVD risk model. The CVD risk model developed in this study is the first to include both albuminuria and eGFR. Diabetic kidney disease is strongly associated with CVD and can be represented in 2 separate manifestations as micro-or macroalbuminuria P value is for the test of significance of the risk factor. CVD indicates cardiovascular disease (ischemic heart disease, ischemic stroke, heart failure and peripheral artery disease); eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; and LDL, low-density lipoprotein.
by guest on April 18, 2017 http://circ.ahajournals.org/ Downloaded from or as impaired glomerular filtration rate. 6 Both manifestations are independent risk factors for CVD, 53, 54 and it is important to adequately include both contributions in a risk equation for CVD.
The extensive clinical data available for the patients in this study enabled us to test predictors such as sodium and potassium, known to be associated with CVD in the general population.
55 Also, TSH was tested, which has been shown to be associated with fatal and nonfatal ischemic heart disease events. 56 However, we did not find sodium, potassium, or TSH to add significantly to the predictive effect for CVD in the present model.
In register studies, lifestyle factors other than smoking are rarely recorded. In our study, we were able to study the predictive effect of both exercise and alcohol intake on CVD risk. However, because smoking, alcohol intake, and physical activity was not recorded in a standardized manner over time, we had to use crude categorizations of these lifestyle indicators. This could suggest that their predictive potential had not been fully used. On the other hand, because these lifestyle indicators are also recorded differently between populations, the use of crude categories in the CVD risk model may increase its feasibility across populations. No information on inflammation was available for this patient population. However, although some studies have linked inflammatory markers to CVD, their predictive ability for CVD above that of other more conventional risk factors is unclear. 6 During follow-up, 182 patients died of causes other than CVD in the population used to derive the prediction model. However, because this number constitutes <5% of the patient population, the effect of competing risk from non-CVD death was considered negligible in this study.
As with all other survival models, the derived model will reflect the treatment practice current at the baseline period. In our case, the baseline spans years from 2001 to 2013. The CVD risk model was developed to support the clinical decision on primary prevention of CVD in T1D. Current risk models for CVD developed for the general population and for type 2 diabetes mellitus have been shown to underestimate CVD risk in T1D, which may partly explain why this group of patients is not in sufficient CVD prophylaxis in comparison with patients with type 2 diabetes mellitus. 13 We have derived a model for prediction of first CVD event in T1D patients which allows the implementation of decision rules in a clinical setting for general clinical use. This model may not only improve clinical decision making for T1D patients, but it may also facilitate a subsequent clinical impact analysis of patient outcomes, a neglected but highly important area.
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Where r IHD or stroke is the annual incidence rate, calculated from the parameters in Supplemental Table 4 Figure 1 . Error rate and variable importance from the random survival tree analysis using the rfsrc function with 300 trees from the randomForestSRC package in R for the composite CVD outcome (ischemic heart disease, ischemic stroke, heart failure and peripheral artery disease)
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Supplemental Figure 2 Survival tree generated from the ctree function from the party package in R for the composite CVD outcome (ischemic heart disease, ischemic stroke, heart failure and peripheral artery disease). AHT: antihypertensive treatment. Alb: albuminuria. eGFR: estimated glomerular filtration rate
